Antipsychotics for Migraines, Cluster Headaches, and Nausea

Total Page:16

File Type:pdf, Size:1020Kb

Antipsychotics for Migraines, Cluster Headaches, and Nausea Web extra Antipsychotics for migraines, cluster headaches, and nausea Evidence of efficacy for these conditions is limited, and risk of side effects may inhibit use ost evidence supporting antipsychotics as a treat- ment for migraine headaches and cluster head- Maches is based on small studies and chart reviews. Some research suggests antipsychotics may effectively treat nausea but side effects such as akathisia may limit their use. Migraine headaches Antipsychotic treatment of migraines is supported by the theory that dopaminergic hyperactivity leads to migraine headaches (Table 1, page E2). Antipsychotics have been used off-label in migraine patients who do not tolerate triptans or have status migrainosus—intense, debilitating migraine JON KRAUSE FOR CURRENT PSYCHIATRY lasting >72 hours.1 Primarily a result of D2 receptor block- ade, the serotonergic effects of some second-generation anti- Aveekshit Tripathi, MD psychotics (SGAs) may prevent migraine recurrence. The Senior Resident Psychiatry and Behavioral Sciences first-generation antipsychotics (FGAs) prochlorperazine, droperidol, haloperidol, and chlorpromazine have been Matthew Macaluso, DO Assistant Professor, Psychiatry and Behavioral Sciences 1-27 used for migraine headaches (Table 2, page E3). Associate Director, Residency Training Prochlorperazine may be an effective treatment of acute • • • • headaches9 and refractory chronic daily headache.10 Studies show that buccal prochlorperazine is more effective than oral University of Kansas School of Medicine-Wichita Wichita, KS ergotamine tartrate11 and IV prochlorperazine is more effective than IV ketorolac12 or valproate28 for treating acute headache. Evidence suggests that chlorpromazine administered IM2 or IV3 is better than placebo for managing migraine pain. In a study comparing IV chlorpromazine, lidocaine, and dihydroergotamine, patients treated with chlorproma- zine showed more persistent headache relief 12 to 24 hours post-dose.4 In another study, IV chlorpromazine, 25 mg, Current Psychiatry was as effective as IM ketorolac, 60 mg.5 Vol. 12, No. 2 E1 continued Table 1 Possible rationale for antipsychotic use for headaches and nausea Condition Possible rationale Migraine Patients are hypersensitive to dopamine agonists or dopamine transporter dysfunction. Some evidence that the dopamine D2 (DRD2) gene is involved Cluster headache Pain alleviation possibly related to dopamine receptor antagonism Headache, nausea, Nausea D2 and H1 receptor blockage and antipsychotics Droperidol has been shown to be effec- headache severity (measured on a 0 to 10 tive for managing headache, specifically scale) from 8.7 ± 1.6 before treatment to 2.2 status migrainosus.6 Patients with “benign ± 2.1 after treatment.16 Researchers found headache”—headache not caused by an that 2.5 or 5 mg of olanzapine relieved underlying medical disorder—who re- acute migraines for most patients, with ceived droperidol reported greater reduc- repeat dosing as needed up to 20 mg/d. Clinical Point tion in visual analog pain scores within 1 For prophylactic treatment, 5 or 10 mg of Primarily a result hour of dosing compared with those tak- olanzapine was used. Olanzapine’s anti- ing prochlorperazine.7 In a randomized nociceptive effect may be related to its ac- of D2 receptor trial comparing IM droperidol and IM me- tion on α-2 adrenoreceptors and to a lesser blockade, the peridine, patients with an acute migraine extent on involvement of opioid and sero- serotonergic effects who received droperidol had improved tonergic receptors.17 of some SGAs may scores on the visual pain analog scale In a case series, 3 migraine patients who and required less “rescue medication” for met criteria for chronic daily headache and prevent migraine breakthrough pain.8 The FDA has issued a migraines but did not have a psychiatric recurrence “black-box” warning of QTc prolongation disorder reported significant and sustained with droperidol. headache improvement when treated with In a double blind, placebo-controlled risperidone.19 In a case series of 3 migraine trial, IV haloperidol, 5 mg, effectively patients with co-occurring psychiatric dis- treated migraine headache in 80% of pa- orders, aripiprazole decreased migraine tients compared with 15% of those who re- frequency and severity.15 Although limited ceived placebo. However, 16% of patients data support quetiapine’s efficacy in treat- considered the side effects—mainly seda- ing acute migraines, in an open-label, pilot tion and akathisia—intolerable and 7% study, patients taking quetiapine, 25 to 75 had symptom relapse.13 In an open-label mg/d, demonstrated a decrease in mean trial of 6 patients with migraine headache, frequency of migraine days from 10.2 to all patients achieved complete or substan- 6.2 and decreased use of rescue medica- tial headache relief 25 to 65 minutes after tions from 2.3 to 1.2 days per week.18 receiving IV haloperidol, 5 mg.14 SGAs often antagonize 5-HT1D recep- tors and theoretically can render triptan Cluster headaches therapy—which stimulates pre-synaptic Subcutaneous sumatriptan and inhaled 5-HT1D receptors—ineffective. This has oxygen are first-line treatments for clus- not been seen clinically and instead, ter headaches.31 A single, small study20 dose-related, non-specific headaches are reported that chlorpromazine may pre- a common adverse event with SGAs.29,30 vent cluster headaches, which suggests A retrospective chart review found olan- that D2 receptor blockade may treat such zapine provided relief for refractory headaches. However, limited supporting headaches in patients who had failed ≥4 evidence relegates its use to a second- or preventive medications. Olanzapine sig- third-line therapy. nificantly decreased headache days, from In an open-label study (N = 5), olanzap- 27.5 ± 4.9 before treatment to 21.1 ± 10.7 ine provided some relief of pain associated Current Psychiatry E2 February 2013 after treatment. Olanzapine also improved with cluster headache within 20 minutes of Table 2 Antipsychotics for headache and nausea: Strength of the evidence Condition Strength of evidencea Migraine Intermediate: Chlorpromazine,2-5 droperidol,6-8 prochlorperazine1,10-12 Weak: Haloperidol13,14 Very weak: Aripiprazole,15 olanzapine,16,17 quetiapine,18 ziprasidone19 Cluster headache Weak: Chlorpromazine20 Very weak: Clozapine,21 olanzapine22 Nausea/vomiting Intermediate: Droperidol,23 metoclopramide,24 prochlorperazine,25 promethazine25 Weak: Olanzapine26,27 aStrong: Multiple, well-designed RCTs directly relevant to the recommendation, yielding consistent findings Intermediate: Some evidence from RCTs that support the recommendation, but the scientific support was not optimal Weak: Consensus recommendation in the absence of relevant randomized controlled trials and better evidence than case report or series Very weak: Case reports or case series or preliminary studies RCTs: randomized controlled trials Clinical Point A small study reports that chlorpromazine administration.22 In another study, patients Metoclopramide is effective for treat- may prevent cluster with schizophrenia and comorbid cluster ing acute migraine and associated nausea24 headaches, which headaches improved with olanzapine.21 and has been used to treat gastroparesis suggests D2 receptor Because evidence is limited to small because of its effect on upper GI motil- blockade may treat prospective studies, antipsychotic treat- ity. Phenothiazines have been used to treat ment of cluster headache is not well es- nausea and studies have shown prochlor- such headaches tablished.20-22 However, olanzapine may perazine to be more effective than prometh- benefit patients with comorbid cluster azine.25 Some studies of prochlorperazine headaches and schizophrenia. have reported a 44% incidence of akathi- sia, which limits the drug’s use in patients who may be sensitive to such effects.33 Nausea Promethazine can cause sedation and risk The signaling pathways that mediate em- of tissue necrosis at the injection site.34 esis involve 5-HT3, D2, muscarinic, and Among SGAs, olanzapine effectively pre- histamine receptors.32 Before 5-HT3 an- vented acute and delayed chemotherapy- tagonists were available, the FGAs meto- induced nausea and vomiting in a proof- clopramide, droperidol, prochlorperazine, of-concept study of patients receiving high and promethazine were used to manage and moderate emetogenic therapies.26,27 acute emesis in emergency departments.23 National Comprehensive Cancer Network A double-blind, placebo-controlled trial guidelines cite olanzapine as a potential found IV droperidol, 1.25 mg, was more option for treating refractory and break- effective than metoclopramide, 10 mg, through emesis.35 In a small study (N = or prochlorperazine, 10 mg, for relieving 50), olanzapine showed comparable anti- moderate to severe nausea in adult pa- nausea effect to aprepitant—a neurokinin tients.23 However, droperidol and prochlor- 1 receptor antagonist—and effectively perazine were associated with akathisia. In prevented chemotherapy-induced nau- addition, this trial did not find a clinically sea and vomiting in highly emetogenic significant difference between groups—in- chemotherapy.36 cluding placebo—in anxiety, sedation, or need for rescue medications.23 Use of dro- References 1. Dusitanond P, Young WB. Neuroleptics and migraine. Cent peridol to treat nausea decreased after the Nerv Syst Agents Med Chem. 2009;9(1):63-70. drug received a “black-box” warning for 2. McEwen JI, O’Connor HM, Dinsdale HB. Treatment of migraine with intramuscular
Recommended publications
  • Prochlorperazine 5Mg Tablets
    Package leaflet: Information for the patient Prochlorperazine 5mg tablets Read all of this leaflet carefully before you start taking this • the person is a child. This is because children may develop unusual face and body medicine, because it contains important information for you. movements (dystonic reactions) • Keep this leaflet. You may need to read it again. • you are diabetic or have high levels of sugar in your blood (hyperglycaemia). Your doctor • If you have any further questions, ask your doctor or pharmacist. may want to monitor you more closely. • This medicine has been prescribed for you only. Do not pass it on to If you are not sure if any of the above apply to you, talk to your doctor or pharmacist before others. It may harm them, even if their signs of illness are the same taking Prochlorperazine Tablets. as yours. Other medicines and Prochlorperazine tablets • If you get any side effects, talk to your doctor or pharmacist. Tell your doctor or pharmacist if you are taking, have recently taken or might take any This includes any possible side effects not listed in this leaflet. other medicines. This includes medicines you buy without a prescription, including herbal See section 4. medicines. This is because Prochlorperazine Tablets can affect the way some other medicines work. What is in this leaflet: Also some medicines can affect the way Prochlorperazine Tablets work. 1 What Prochlorperazine tablets are and what they In particular, tell your doctor if you are taking any of the following: • medicines to help you sleep
    [Show full text]
  • Centre for Reviews and Dissemination
    Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta- analysis Leucht S, Corves C, D Arbter, Engel R R, Li C, Davis J M CRD summary The authors concluded that amisulpride, clozapine, olanzapine and risperidone can be effective in treating schizophrenia patients. Second-generation antipsychotic drugs can also result in fewer extrapyramidal side effects, but can induce weight gain. The authors' conclusions reflected the evidence presented, but some potential methodological flaws in the review process meant that the extent to which those conclusions were reliable was unclear. Authors' objectives To compare the effects of first and second-generation antipsychotic drugs in schizophrenia patients. Searching The search for eligible studies was started in 2005, including MEDLINE to October 2006, Cochrane Schizophrenia Group's Specialised Register and the US Food and Drugs Administration website. Search terms were reported and there were no language restrictions. Previous reviews were searched for additional relevant studies. Study selection Randomised controlled trials (RCTs) of oral second-generation antipsychotic drugs (amisulpride, aripiprazole, clozapine, olanzapine, quetiapine, risperidone, sertindole, ziprasidone and zotepine) compared with first-generation drugs in patients with schizophrenia or related disorders (schizoaffective, schizophreniform or delusional disorders) irrespective of diagnostic criteria were eligible for inclusion in the review. The optimum doses of second-generation drugs were selected
    [Show full text]
  • Free PDF Download
    European Review for Medical and Pharmacological Sciences 2021; 25: 4746-4756 Pathophysiology and management of Akathisia 70 years after the introduction of the chlorpromazine, the first antipsychotic N. ZAREIFOPOULOS1, M. KATSARAKI1, P. STRATOS1, V. VILLIOTOU, M. SKALTSA1, A. DIMITRIOU1, M. KARVELI1, P. EFTHIMIOU2, M. LAGADINOU2, D. VELISSARIS3 1Department of Psychiatry, General Hospital of Nikea and Pireus Hagios Panteleimon, Athens, Greece 2Emergency Department, University General Hospital of Patras, Athens, Greece 3Department of Internal Medicine, University of Patras School of Medicine, Athens, Greece Abstract. – OBJECTIVE: Akathisia is among CONCLUSIONS: Pharmacological manage- the most troubling effects of psychiatric drugs ment may pose a challenge in chronic akathi- as it is associated with significant distress on sia. Rotation between different pharmacologi- behalf of the patients, and it limits treatment ad- cal management strategies may be optimal in re- herence. Though it most commonly presents sistant cases. Discontinuation of the causative during treatment with antipsychotic drugs which drug and use of b-blockers, mirtazapine, benzo- block dopamine D2 receptors, Akathisia has al- diazepines or gabapentinoids for symptomatic so been reported during treatment with selec- relief is the basis of management. tive serotonin reuptake inhibitors (SSRIs), se- rotonin norepinephrine reuptake inhibitors (SN- Key Words: RIs), stimulants, mirtazapine, tetrabenazine and Aripiprazole, Extrapyramidal symptoms, Haloperi- other drugs. dol,
    [Show full text]
  • Pharmacotherapy, Drug-Drug Interactions and Potentially
    medRxiv preprint doi: https://doi.org/10.1101/2021.03.31.21254518; this version posted April 6, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Pharmacotherapy, drug-drug interactions and potentially inappropriate medication in depressive disorders Jan Wolff1,2,3, Pamela Reißner4, Gudrun Hefner5, Claus Normann2, Klaus Kaier6, Harald Binder6, Christoph Hiemke7, Sermin Toto8, Katharina Domschke2, Michael Marschollek1, Ansgar Klimke4,9 1 Peter L. Reichertz Institute for Medical Informatics of TU Braunschweig and Hannover Medical School, Germany. 2 Department of Psychiatry and Psychotherapy, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany. 3 Evangelical Foundation NeuerKerode, Germany. 4 Vitos Hochtaunus, Friedrichsdorf, Germany. 5 Vitos Clinic for Forensic Psychiatry, Eltville, Germany 6 Institute of Medical Biometry and Statistics, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Germany. 7 Department of Psychiatry and Psychotherapy, University Medical Center Mainz, Germany. 8 Department of Psychiatry, Social Psychiatry and Psychotherapy, Hannover Medical School, Germany. 9 Heinrich-Heine-University Düsseldorf, Germany. ___ Correspondence Dr. Jan Wolff, Peter L. Reichertz Institute for Medical Informatics of TU Braunschweig and Hannover Medical School, Hannover, Germany. Address: Karl- Wiechert-Allee 3, 30625 Hannover. Email: [email protected], wolff.jan@mh- hannover.de, ORCID: https://orcid.org/0000-0003-2750-0606 Key words (MeSH) Depression, Polypharmacy, Antidepressants, Hospitals, Drug Interactions, Psychiatry NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
    [Show full text]
  • Sibelium 5 Mg Tablets
    PACKAGE LEAFLET: INFORMATION FOR THE USER Sibelium 5 mg Tablets flunarizine Read all of this leaflet carefully before you start taking this medicine because it contains important information for you. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4. In this leaflet: 1. What Sibelium is and what it is used for 2. What you need to know before you take Sibelium 3. How to take Sibelium 4. Possible side effects 5. How to store Sibelium 6. Contents of the pack and other information 1. WHAT SIBELIUM IS AND WHAT IT IS USED FOR What is Sibelium? Sibelium tablets contain flunarizine. They belong to a group of medicines known as calcium channel blockers, which work by preventing the narrowing of blood vessels. What is it used for? Sibelium Tablets are for use in adults. They have been prescribed for you to help your migraine-type headaches. If you take Sibelium Tablets regularly they can help you get fewer headaches, or less painful headaches. They can stop some migraine attacks starting and help make other attacks less severe. While you are taking Sibelium Tablets, your doctor will review your treatment at regular intervals in order to assess your response to the medicine.
    [Show full text]
  • The Effects of Antipsychotic Treatment on Metabolic Function: a Systematic Review and Network Meta-Analysis
    The effects of antipsychotic treatment on metabolic function: a systematic review and network meta-analysis Toby Pillinger, Robert McCutcheon, Luke Vano, Katherine Beck, Guy Hindley, Atheeshaan Arumuham, Yuya Mizuno, Sridhar Natesan, Orestis Efthimiou, Andrea Cipriani, Oliver Howes ****PROTOCOL**** Review questions 1. What is the magnitude of metabolic dysregulation (defined as alterations in fasting glucose, total cholesterol, low density lipoprotein (LDL) cholesterol, high density lipoprotein (HDL) cholesterol, and triglyceride levels) and alterations in body weight and body mass index associated with short-term (‘acute’) antipsychotic treatment in individuals with schizophrenia? 2. Does baseline physiology (e.g. body weight) and demographics (e.g. age) of patients predict magnitude of antipsychotic-associated metabolic dysregulation? 3. Are alterations in metabolic parameters over time associated with alterations in degree of psychopathology? 1 Searches We plan to search EMBASE, PsycINFO, and MEDLINE from inception using the following terms: 1 (Acepromazine or Acetophenazine or Amisulpride or Aripiprazole or Asenapine or Benperidol or Blonanserin or Bromperidol or Butaperazine or Carpipramine or Chlorproethazine or Chlorpromazine or Chlorprothixene or Clocapramine or Clopenthixol or Clopentixol or Clothiapine or Clotiapine or Clozapine or Cyamemazine or Cyamepromazine or Dixyrazine or Droperidol or Fluanisone or Flupehenazine or Flupenthixol or Flupentixol or Fluphenazine or Fluspirilen or Fluspirilene or Haloperidol or Iloperidone
    [Show full text]
  • Management of Major Depressive Disorder Clinical Practice Guidelines May 2014
    Federal Bureau of Prisons Management of Major Depressive Disorder Clinical Practice Guidelines May 2014 Table of Contents 1. Purpose ............................................................................................................................................. 1 2. Introduction ...................................................................................................................................... 1 Natural History ................................................................................................................................. 2 Special Considerations ...................................................................................................................... 2 3. Screening ........................................................................................................................................... 3 Screening Questions .......................................................................................................................... 3 Further Screening Methods................................................................................................................ 4 4. Diagnosis ........................................................................................................................................... 4 Depression: Three Levels of Severity ............................................................................................... 4 Clinical Interview and Documentation of Risk Assessment...............................................................
    [Show full text]
  • Long-Term Care Updates
    Long-Term Care Updates October 2017 By Alyson Lozicki, PharmD The treatment of migraine symptoms in elderly patients is similar to treatment in younger adults. For all patients, the selection of a pharmacological agent should be based on patient- specific factors and migraine severity, and greater caution should be exercised for older adults due to an increased prevalence of comorbid conditions and risk of adverse effects. Because of this, options for drug therapy in the elderly are limited, but this population tends to have a better response to acute treatment in comparison to a younger cohort.1-3 Of the drugs that have established efficacy in the treatment of migraine, acetaminophen, triptans, ergotamine, opioids, and antiemetics can be appropriate options for elderly patients. Acetaminophen is the safest option and is the drug of choice for most patients with non- debilitating symptoms of migraine.2-4 The choice of therapy for patients with moderate- severe symptoms should be based on comorbid conditions, potential drug-drug interactions, and the risk of serious adverse effects. However, the adverse effect profile of a medication does not preclude its use.3 General recommendations and safety considerations are outlined in Table 1; some of these medications do appear on the Beers List with a strong recommendation to avoid due to increased risk of falls and fracture. Additionally, certain medications used to treat migraine in younger patients should be avoided in older adults due to the increased risk of serious adverse events. These include acetylsalicylic acid, nonsteroidal anti-inflammatory drugs (NSAIDs), barbiturate-containing drugs, flunarizine, www.creighton.edu/ 1-5 and tricyclic antidepressants (Table 2).
    [Show full text]
  • A Comparative Effectiveness Meta-Analysis of Drugs for the Prophylaxis of Migraine Headache
    University of South Florida Masthead Logo Scholar Commons School of Information Faculty Publications School of Information 7-2015 A Comparative Effectiveness Meta-Analysis of Drugs for the Prophylaxis of Migraine Headache Authors: Jeffrey L. Jackson, Elizabeth Cogbill, Rafael Santana-Davila, Christina Eldredge, William Collier, Andrew Gradall, Neha Sehgal, and Jessica Kuester OBJECTIVE: To compare the effectiveness and side effects of migraine prophylactic medications. DESIGN: We performed a network meta-analysis. Data were extracted independently in duplicate and quality was assessed using both the JADAD and Cochrane Risk of Bias instruments. Data were pooled and network meta-analysis performed using random effects models. DATA SOURCES: PUBMED, EMBASE, Cochrane Trial Registry, bibliography of retrieved articles through 18 May 2014. ELIGIBILITY CRITERIA FOR SELECTING STUDIES: We included randomized controlled trials of adults with migraine headaches of at least 4 weeks in duration. RESULTS: Placebo controlled trials included alpha blockers (n = 9), angiotensin converting enzyme inhibitors (n = 3), angiotensin receptor blockers (n = 3), anticonvulsants (n = 32), beta-blockers (n = 39), calcium channel blockers (n = 12), flunarizine (n = 7), serotonin reuptake inhibitors (n = 6), serotonin norepinephrine reuptake inhibitors (n = 1) serotonin agonists (n = 9) and tricyclic antidepressants (n = 11). In addition there were 53 trials comparing different drugs. Drugs with at least 3 trials that were more effective than placebo for episodic migraines
    [Show full text]
  • Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanismss
    Supplemental Material can be found at: /content/suppl/2020/12/18/73.1.202.DC1.html 1521-0081/73/1/202–277$35.00 https://doi.org/10.1124/pharmrev.120.000056 PHARMACOLOGICAL REVIEWS Pharmacol Rev 73:202–277, January 2021 Copyright © 2020 by The Author(s) This is an open access article distributed under the CC BY-NC Attribution 4.0 International license. ASSOCIATE EDITOR: MICHAEL NADER Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanismss Antonio Inserra, Danilo De Gregorio, and Gabriella Gobbi Neurobiological Psychiatry Unit, Department of Psychiatry, McGill University, Montreal, Quebec, Canada Abstract ...................................................................................205 Significance Statement. ..................................................................205 I. Introduction . ..............................................................................205 A. Review Outline ........................................................................205 B. Psychiatric Disorders and the Need for Novel Pharmacotherapies .......................206 C. Psychedelic Compounds as Novel Therapeutics in Psychiatry: Overview and Comparison with Current Available Treatments . .....................................206 D. Classical or Serotonergic Psychedelics versus Nonclassical Psychedelics: Definition ......208 Downloaded from E. Dissociative Anesthetics................................................................209 F. Empathogens-Entactogens . ............................................................209
    [Show full text]
  • Managing Migraine
    NEUROLOGY/EXPERT CLINICAL MANAGEMENT Managing Migraine Benjamin W. Friedman, MD, MS* *Corresponding Author. E-mail: [email protected], Twitter: @benjaminbwf. 0196-0644/$-see front matter Copyright © 2016 by the American College of Emergency Physicians. http://dx.doi.org/10.1016/j.annemergmed.2016.06.023 A podcast for this article is available at www.annemergmed.com. alertness, and appetite. Allodynia, an alteration of Continuing Medical Education exam for this article is available at nociception that causes typically non-noxious sensory http://www.acep.org/ACEPeCME/. stimuli (such as brushing one’s hair or shaving one’s face) to be perceived as painful, develops as acute migraine duration [Ann Emerg Med. 2017;69:202-207.] increases. This is thought to indicate involvement of higher-order central nervous system sensory relay stations, Editor’s Note: The Expert Clinical Management series notably, the thalamus. consists of shorter, practical review articles focused on the optimal approach to a specific sign, symptom, disease, Migraine was once believed to be a vascular headache. procedure, technology, or other emergency department Advanced imaging studies do not support this description challenge. These articles–typically solicited from and indicate that migraine is a neurologic disorder involving recognized experts in the subject area–will summarize the dysfunctional nociceptive processing.3 Abnormally activated best available evidence relating to the topic while including sensory pathways turn non-noxious stimuli into headache, practical recommendations where the evidence is photophobia, phonophobia, and osmophobia. Cortical incomplete or conflicting. spreading depression, a slow wave of brain depolarization, underlies migraine aura but has not been demonstrated clearly in migraine patients without aura.
    [Show full text]
  • Aggression and Agitation in Dementia, None of Which Are Approved by the US Food and Drug Administration
    REVIEW ARTICLE 07/09/2018 on SruuCyaLiGD/095xRqJ2PzgDYuM98ZB494KP9rwScvIkQrYai2aioRZDTyulujJ/fqPksscQKqke3QAnIva1ZqwEKekuwNqyUWcnSLnClNQLfnPrUdnEcDXOJLeG3sr/HuiNevTSNcdMFp1i4FoTX9EXYGXm/fCfl4vTgtAk5QA/xTymSTD9kwHmmkNHlYfO by https://journals.lww.com/continuum from Downloaded Aggression and Agitation CONTINUUM AUDIO Downloaded INTERVIEW AVAILABLE in Dementia ONLINE from By M. Uri Wolf, MD, FRCPC; Yael Goldberg, PhD, CPsych; https://journals.lww.com/continuum Morris Freedman, MD, FRCPC, FAAN CITE AS: CONTINUUM (MINNEAP MINN) 2018;24(3,BEHAVIORALNEUROLOGY AND PSYCHIATRY):783–803. ABSTRACT Address correspondence to by Dr M. Uri Wolf, Baycrest Health SruuCyaLiGD/095xRqJ2PzgDYuM98ZB494KP9rwScvIkQrYai2aioRZDTyulujJ/fqPksscQKqke3QAnIva1ZqwEKekuwNqyUWcnSLnClNQLfnPrUdnEcDXOJLeG3sr/HuiNevTSNcdMFp1i4FoTX9EXYGXm/fCfl4vTgtAk5QA/xTymSTD9kwHmmkNHlYfO PURPOSEOFREVIEW: This article reviews the treatment of aggression and Sciences, 3560 Bathurst St, agitation in dementia. Both nonpharmacologic and pharmacologic Toronto, ON M6A 2E1, Canada, approaches to responsive behaviors are discussed. Practical treatment [email protected]. strategies are applied to common behavioral symptoms. RELATIONSHIP DISCLOSURE: Drs Wolf and Goldberg report no disclosures. Dr Freedman serves RECENT FINDINGS: Aggressive and agitated behavior is common in dementia. as a trustee for the World Behavioral symptoms lead to reduced quality of life and distress for both Federation of Neurology and on patients and caregivers. They can also lead to poor outcomes and are the editorial boards
    [Show full text]